The Society for Vascular Medicine (SVM) is a part of a coalition of five leading nonprofit professional societies that has made recommendations for the treatment of peripheral artery disease (PAD) to the Centers for Medicare and Medicaid Services (CMS) Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) panel. The coalition’s recommendations are explained in an editorial that will appear in Vascular Medicine, the official journal of SVM. The editorial was made available on April 10 on the Vascular Medicine website.
The MEDCAC panel was convened to examine scientific evidence for lower-extremity PAD treatments that aim to improve health outcomes in Medicare beneficiaries and to address areas where evidence gaps exit related to lower-extremity PAD. The panel discussed care for patients with three levels of peripheral artery disease: asymptomatic, intermittent claudication, and critical limb ischemia.
The Society for Vascular Medicine has released a list of “Five Things Physicians and Patients Should Question” in vascular medicine as part of the Choosing Wisely® campaign, led by the ABIM Foundation. The list identifies five targeted, evidence-based recommendations that can support physicians and patients in making wise choices about their care. Download the list.
SVM Calls USPSTF
Coronary Heart Disease Recommendations Ill-advised
The Society for Vascular Medicine (SVM) finds these Task Force recommendations, particularly those discouraging the use of ankle-brachial index (ABI) screening for peripheral arterial disease (PAD), ill-advised and contrary to sound medical research. In a 2006 publication, the Task Force dismissed PAD as an important risk factor in cardiovascular disease. However, PAD is not merely a risk factor for cardiovascular disease, it is cardiovascular disease. PAD is thought to affect 8 - 10 million Americans. Individuals with PAD have a five-times increased risk of suffering an heart attack, stroke, or death within five years.